article thumbnail

4mn dose shortage of GSK’s childhood rotavirus vaccine expected

European Pharmaceutical Review

According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK. First dose measles coverage dropped to 81 percent in 2021, the lowest level since 2008, meaning 24.7

article thumbnail

STAT+: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine

STAT

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.

Vaccines 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study shows HPV jab almost 90% effective at preventing cervical cancer

pharmaphorum

Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The first vaccine used was GlaxoSmithKline’s Cervarix, which was replaced by MSD’s Gardasil in 2012.

Vaccines 105
article thumbnail

MSD Ireland’s €1b facility investment achieves new milestone

European Pharmaceutical Review

In total, both projects represent an investment of over €1 billion” MSD Carlow runs as filling site for the launch and commercial supply of vaccines , biologics, and small molecule drug products. Opened in 2008, the facility was MSD’s first vaccines operation outside of the US. MSD Dunboyne in Co.

article thumbnail

Moderna and BioNTech – who are they?

pharmaphorum

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111
article thumbnail

Are we globally prepared for the next pandemic?

European Pharmaceutical Review

Vaccitech’s Chief Business Officer, Graham Griffiths, discusses key learnings in drug and vaccine development , the challenges of preparing for the unknown, and how strategic collaboration is imperative to achieve faster and more equitable outcomes – if and when another pandemic strikes.

Vaccines 114
article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

When Milburn and Blair introduced competition in 2004-2008 it did start to make a difference.” Since 2008, the budget for NHS has grown 1% and the market 4%. The vaccine programme is the best example,” Lord Prior said. Highly unlikely.” Berry asked whether that included incentives or penalties.